Werewolf Therapeutics, Inc. - Common Stock (NQ:HOWL)

0.9399 +0.0099 (+1.06%)

Delayed Quote Updated: 3:16 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Werewolf Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

12 Health Care Stocks Moving In Friday's Intraday Session ↗

November 03, 2023

Via Benzinga

Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

November 03, 2023

Gainers Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740.

Via Benzinga

Expert Ratings for Werewolf Therapeutics ↗

May 11, 2023

Via Benzinga

Recap: Werewolf Therapeutics Q1 Earnings ↗

May 11, 2023

Via Benzinga

Analyst Ratings for Werewolf Therapeutics ↗

March 24, 2023

Via Benzinga

Delta Air Lines Layoffs 2023: What to Know About the Latest DAL Job Cuts ↗

November 03, 2023

Delta Air Lines layoffs have the air travel company announcing minor adjustments to its corporate and management positions.

Via InvestorPlace

Topics Workforce

CVNA Stock Alert: What Analysts Are Saying After Carvana’s Q3 Earnings ↗

November 03, 2023

Carvana stock is on the move as analysts weigh in on CVNA shares following the release of the company's latest earnings report.

Via InvestorPlace

Why Is Werewolf Therapeutics (HOWL) Stock Up 20% Today? ↗

November 03, 2023

Werewolf Therapeutics stock is taking off with heavy trading of HOWL shares after posting preliminary data from a clinical trial.

Via InvestorPlace

Werewolf Therapeutics' Cancer Drug Shows Promise in Early Study for Solid Tumors, Stock Soars ↗

November 03, 2023

Werewolf Therapeutics Inc (NASDAQ: HOWL) released preliminary results from initial monotherapy dose-escalation cohorts of an ongoing Phase 1/1b trial of WTX-124 in patients with advanced or

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

November 03, 2023

Via Benzinga

Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

November 03, 2023

From Werewolf Therapeutics, Inc.

Via GlobeNewswire

Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

November 02, 2023

Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholders.

Via Benzinga

Why Roku Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket ↗

November 02, 2023

Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 39.7% to $0.1143 in pre-market trading after falling 17% on Wednesday. LumiraDX recently announced the receipt of the Nasdaq delisting...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

November 02, 2023

Pre-market stock movers are a hot topic on Thursday and we're checking out all of the biggest ones worth watching this morning!

Via InvestorPlace

Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

October 31, 2023

From Werewolf Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 25, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

October 12, 2023

Pre-market stock movers are a hot topic among traders on Thursday and we're offering all of the latest coverage this morning!

Via InvestorPlace

Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

September 27, 2023

From Werewolf Therapeutics, Inc.

Via GlobeNewswire

Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124

September 11, 2023

Virtual event to be held on Monday, September 18, 2023, at 10:00 am ET

From Werewolf Therapeutics, Inc.

Via GlobeNewswire

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

September 05, 2023

From Werewolf Therapeutics, Inc.

Via GlobeNewswire

Small Cancer Player Werewolf Therapeutics' Stock Undervalued: Analyst Says Treatment Platform Underappreciated ↗

August 24, 2023

Wedbush initiated coverage on Werewolf Therapeutics Inc (NASDAQ: HOWL) with an Outperform rating and a

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

August 24, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2023 ↗

August 24, 2023

Via Benzinga

Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

August 10, 2023

From Werewolf Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

June 08, 2023

Via Benzinga

Werewolf Therapeutics to Present at the Jefferies Healthcare Conference

June 01, 2023

From Werewolf Therapeutics, Inc.

Via GlobeNewswire

Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 11, 2023

From Werewolf Therapeutics, Inc.

Via GlobeNewswire

Werewolf Therapeutics to Participate in May Investor Conferences

May 01, 2023

From Werewolf Therapeutics, Inc.

Via GlobeNewswire

Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology Research

April 19, 2023

From Werewolf Therapeutics, Inc.

Via GlobeNewswire

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 23, 2023

From Werewolf Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.